文献速递眼底病与葡萄膜炎

莫菲尔德年龄相关性黄斑变性数据库报告2:新生血管性年龄相关性黄斑变性的对侧眼受累情况

Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration.
PubMed 文献 · Br J Ophthalmol · 2019-10-14

该回顾性电子病历数据库研究分析了莫菲尔德年龄相关性黄斑变性数据库中6265例患者的数据,旨在探讨新生血管性年龄相关性黄斑变性对侧眼受累的基线特征和视力结局,并区分序贯与非序贯(因第一眼黄斑瘢痕)抗血管内皮生长因子治疗及对侧眼受累时间线。结果显示,序贯治疗的对侧眼基线及2年最终视力均优于非序贯治疗眼,且序贯治疗眼具有良好视力的比例更高;对侧眼2年受累率为32%,中位受累时间间隔为71周。

要点

  • 序贯治疗的对侧眼基线视力(63±13)和2年视力增益(0.37±14)均优于第一眼(基线54±16,增益5.6±15)。
  • 序贯治疗的对侧眼2年后具有良好视力(≥70字母)的比例为46%,高于第一眼的39%。
  • 对侧眼2年受累率为32%,中位受累时间间隔为71周(IQR:27-147)。

核心结论

  • 序贯治疗的新生血管性年龄相关性黄斑变性对侧眼在治疗2年后的基线及最终视力均优于非序贯治疗眼,且具有良好视力的比例更高。

研究设计与样本

  • 回顾性电子病历数据库研究,基于莫菲尔德年龄相关性黄斑变性数据库,纳入6265例患者/120286条记录,数据提取时间为2008年10月21日至2018年8月9日。
  • 分析数据集包括1180只序贯治疗眼、807只非序贯治疗眼和3410只单侧眼。

主要发现

  • 序贯治疗的对侧眼基线平均视力(ETDRS字母±SD)为63±13,2年视力增益为0.37±14,具有良好视力(≥70字母)的比例为46%。
  • 相应第一眼的基线视力为54±16,2年视力增益为5.6±15,具有良好视力的比例为39%。
  • 非序贯治疗的对侧眼基线特征和视力结局与第一眼相似。
  • 对侧眼2年受累率为32%,中位受累时间间隔为71周(IQR:27-147)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Neovascular age-related macular degeneration (nAMD) is frequently bilateral, and previous reports on 'fellow eyes' have assumed sequential treatment after a period of treatment of the first eye only. The aim of our study was to analyse baseline characteristics and visual acuity (VA) outcomes of fellow eye involvement with nAMD, specifically differentiating between sequential and non-sequential (due to macular scarring in the first eye) antivascular endothelial growth factor treatment and timelines for fellow eye involvement. METHODS: Retrospective, electronic medical record database study of the Moorfields AMD database of 6265 patients/120 286 single entries with data extracted between 21 October 2008 and 9 August 2018. The data set for analysis consisted of 1180 sequential, 807 non-sequential and 3410 unilateral eyes. RESULTS: Mean VA (ETDRS letters±SD) of sequentially treated fellow eyes at baseline was significantly higher (63±13), VA gain over 2 years lower (0.37±14) and proportion of eyes with good VA (≥70 letters) higher (46%) than the respective first eyes (baseline VA 54±16, VA gain at 2 years 5.6±15, percentage of eyes with good VA 39%). Non-sequential fellow eyes showed baseline characteristics and VA outcomes similar to first eyes. Fellow eye involvement rate was 32% at 2 years, and median time interval to fellow eye involvement was 71 (IQR: 27-147) weeks. CONCLUSION: This report shows that sequentially treated nAMD fellow eyes have better baseline and final VA than non-sequentially treated eyes after 2 years of treatment. Sequentially treated eyes also had a greater proportion with good VA after 2 years.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Fasler K, Fu DJ, Moraes G, et al. Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration. Br J Ophthalmol. 2019. PMID: 31611234. doi:10.1136/bjophthalmol-2019-314446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。